Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585033 | 0.91 | ATR (0.46) | ATRPLAUMAPK1KDM4EADORA2A | |
| SCHEMBL4584311 | 0.84 | ALDH1A1 (0.48) | ATRMAPK1KDM4ELMNAMAPT | |
| SCHEMBL4586323 | 0.84 | ATR (0.44) | ATRPLAUMAPK1KDM4EADORA2A | |
| SCHEMBL3866288 | 0.84 | PLAU (0.59) | PLAUMAPK1KDM4ELMNAADORA2A | |
| SCHEMBL4583921 | 0.77 | USP8 (0.50) | ATRKDM4ELMNAADORA2AXDH | |
| SCHEMBL5703293 | 0.74 | PLAU (0.40) | PLAUMAPK1KDM4ELMNAADORA2A | |
| SCHEMBL4584433 | 0.74 | ADORA2A (0.56) | PLAUADORA2A | |
| SCHEMBL21722434 | 0.73 | ADORA2A (0.56) | PLAUADORA2A | |
| SCHEMBL3864268 | 0.72 | PLAU (0.54) | PLAUMAPK1KDM4ELMNAXDH | |
| SCHEMBL11374767 | 0.72 | PLAU (0.54) | PLAUKDM4ELMNAXDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| CN-1871231-A | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC (JP) | 2006-11-29 | — | — | CN | disclosed |
| EP-1678160-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Astellas Pharma Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| WO-2005040151-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ASTELLAS PHARMA INC. (JP) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | ATR 3727/4885PLAU 1420/4885MAPK1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.